I was going to say the same thing -- that a lower dose given daily over an extended period might work well on SA. But I guess that's obvious. The pertinent question is would a BP or other entity be interested in a further study based on this data.
I'm tired of all the hypothesizing and speculating. I just want management finally, and once and for all, to deliver. Oh no, I guess that puts me in the same camp as Blatch now. And Haysaw. And Davidal. And others.
But I still don't despair. SA, RD, ADHD, MJFF (and PD), Servier, AD, sz, dep -- gee, there are a lot of possibilities here and I really wouldn't be surprised if something clicks sometime soon.
Market Data 
Markets 
AI
